Is Lenvatinib a targeted drug or an immune drug?

Lenvatinib is considered a targeted therapy, not a chemotherapy drug. Targeted cancer treatments work by affecting specific target molecules that cause cancer to grow and spread. Lenvatinib helps cancer survive by blocking cellular proteins and signals that target blood vessels. These types of drugs are often referred to as "precision medicine," and lenvatinib belongs to a class of drugs called vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs).

Targeted therapies are specifically designed to interact with their targets, rather than with all cells in general (although they may affect other cells and cause side effects). Targeted drugs block the growth of tumor cells (inhibit cell growth), while standard chemotherapy drugs usually kill tumor cells directly (are cytotoxic). Targeted drug therapy can be used alone or in combination with other cancer therapies. For example, lenvatinib is used in combination with the immunotherapy pembrolizumab to treat endometrial cancer.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. The price of 4mg*30 tablets per box may be more than 3,000 yuan. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be around RMB 800 (the price may fluctuate due to exchange rates).